erleada
janssen-cilag international nv - apalutamide - prostata neoplasmer - endokrin terapi - erleada er angitt:i voksne menn for behandling av metastatisk ikke kastrering motstandsdyktig mot prostatakreft (nmcrpc) som har høy risiko for å utvikle metastatisk sykdom. i voksne menn for behandling av metastatisk hormone-sensitive prostatakreft (mhspc) i kombinasjon med androgen mangel terapi (adt).
clarithromycin accord 500 mg
accord healthcare b.v. - klaritromycin - tablett, filmdrasjert - 500 mg
clarithromycin accord 250 mg
accord healthcare b.v. - klaritromycin - tablett, filmdrasjert - 250 mg
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirale midler til systemisk bruk - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
alitretinoin orifarm 10 mg
orifarm generics a/s - alitretinoin - kapsel, myk - 10 mg
alitretinoin orifarm 30 mg
orifarm generics a/s - alitretinoin - kapsel, myk - 30 mg
cabazitaxel accord
accord healthcare s.l.u. - cabazitaxel - prostatic neoplasmer, kastrering-resistant - antineoplastiske midler - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
cabazitaxel stada 20 mg/ ml
stada arzneimittel ag - kabazitaksel - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
pyrukynd
agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.